Karen Rosen-Wasserman, DO
Pain Medicine · Warren, MINPI 1679932206
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,578 of the $5,546 with a category attached, or 82.5%. It is spread thinly across 37 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,969 and has fallen 96.4% since, to $71 in 2025.
Across 251 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nalu Medical, Inc.$1K
- AbbVie$896
- Lundbeck LLC$307
- UCB, Inc.$304
- EMD Serono, Inc.$301
- SK Life Science, Inc.$279
- plus $2K from 31 others
What the payments were for
- Travel & lodging$96817%
- Food & beverage$4,57883%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nalu Medical, Inc. | 11 | $1,182 |
| AbbVie(2 entities) | 46 | $896 |
| Lundbeck LLC | 19 | $307 |
| UCB, Inc. | 25 | $304 |
| EMD Serono, Inc. | 18 | $301 |
| SK Life Science, Inc. | 12 | $279 |
| Eisai Inc. | 10 | $235 |
| TG Therapeutics, Inc. | 10 | $214 |
| Neurocrine Biosciences, Inc. | 11 | $203 |
| ANI Pharmaceuticals, Inc. | 10 | $172 |
| Catalyst Pharmaceuticals, Inc. | 9 | $160 |
| Lilly USA, LLC | 10 | $150 |
| Pfizer | 7 | $114 |
| Neurelis, Inc. | 6 | $104 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $87 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
| Argenx US, Inc. | 4 | $74 |
| CSL Behring | 4 | $71 |
| Nevro Corp. | 2 | $66 |
| Vanda Pharmaceuticals Inc. | 3 | $54 |
| Teva Pharmaceuticals USA, Inc. | 4 | $53 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $47 |
| Medtronic(2 entities) | 2 | $43 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Boston Scientific | 1 | $36 |
| Merz Pharmaceuticals, LLC | 1 | $34 |
| Genentech USA, Inc. | 2 | $32 |
| Johnson & Johnson | 1 | $28 |
| Vertex | 1 | $27 |
| Vertos Medical, Inc. | 1 | $24 |
| Octapharma USA, Inc. | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Tanabe Pharma America, Inc. | 1 | $20 |
| Cycle Pharmaceuticals Inc | 1 | $19 |
| Abbott | 1 | $18 |
| Aucta Pharmaceuticals, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,546 in reported general payments places this provider in the 70th percentile of 139 pain medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 32 | $27,799 |
| Xtampza ErOxycodone Myristate | 38 | $20,973 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 858 | $16,786 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 557 | $11,970 |
| Fentanyl | 80 | $11,390 |
| Morphine Sulfate ErMorphine Sulfate | 245 | $8,015 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 27 | $6,122 |
| Gabapentin | 368 | $5,510 |
| Naloxone Hcl | 63 | $4,663 |
| Oxycodone Hcl | 114 | $2,148 |
| Pregabalin | 175 | $2,071 |
| Duloxetine Hcl | 75 | $2,032 |
| Buprenorphine Hcl | 17 | $1,257 |
| Cyclobenzaprine Hcl | 180 | $1,220 |
| Topiramate | 27 | $1,208 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Warren
- Harry SukumaranRochester Hills$304K
- Nasir KhatriFlint$133K
- Yijia ChuGrand Rapids$88K
- Mark MounayerSouthfield$85K
- Jeffrey RosenbergCanton$44K
- Alexander TurfeWyandotte$41K
- Kendall GroseWyandotte$26K
- Craig HartrickRoyal Oak$26K
- Patrick ForrestAnn Arbor$23K
- Anmar DalatiDetroit$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.